Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.37 |
| ▸ | KIT | P10721 | 10/20 | 0.36 |
| ▸ | KDR | P35968 | 10/20 | 0.36 |
| ▸ | FLT3 | P36888 | 7/20 | 0.36 |
| ▸ | MET | P08581 | 3/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30923936 | 0.93 | KIT (0.38) | TP53SMN1; SMN2KITKDRFLT3 | |
| SCHEMBL30923945 | 0.89 | SCN9A (0.38) | TP53SMN1; SMN2SCN9AKITKDR | |
| SCHEMBL30923949 | 0.89 | SCN9A (0.36) | TP53SMN1; SMN2SCN9AKITKDR | |
| SCHEMBL30923944 | 0.88 | TP53 (0.38) | TP53SMN1; SMN2SCN9AKITKDR | |
| SCHEMBL30924011 | 0.87 | SCN9A (0.38) | TP53SMN1; SMN2SCN9ASCN5ACHRM3 | |
| SCHEMBL30923971 | 0.81 | HPGD (0.30) | — | |
| SCHEMBL30924013 | 0.80 | THRB (0.32) | TP53SMN1; SMN2SCN9A | |
| SCHEMBL573398 | 0.76 | SMN1; SMN2 (0.50) | TP53SMN1; SMN2 | |
| SCHEMBL30923989 | 0.74 | — | — | |
| SCHEMBL27219885 | 0.70 | KIT (0.33) | TP53SMN1; SMN2KITKDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534471-B2 | Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-27 | — | — | US | disclosed |
| EP-4612145-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2025-09-10 | — | — | EP | disclosed |
| US-20240317765-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-26 | — | — | US | disclosed |
| US-20240174677-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-30 | — | — | US | disclosed |
| WO-2024095133-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317765-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NPY2R | TP53 4883/4885SMN1; SMN2 809/4885SCN9A 688/4885 |
| US-20240174677-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NPY2R | TP53 4883/4885SMN1; SMN2 809/4885SCN9A 688/4885 |
| US-12534471-B2 | Pyrrolo[1, 2-c]imidazole derivatives as orexin type 2 receptor agonists and methods of use thereof | HCRTR2, HCRTR1, NPY1R | TP53 4861/4885SMN1; SMN2 723/4885SCN9A 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.